Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 15/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22305208 | 0.90 | CYP2D6 (0.53) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL17285924 | 0.88 | CYP2D6 (0.47) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1TSHR | |
| SCHEMBL22477427 | 0.88 | CYP2D6 (0.59) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL18926698 | 0.85 | CYP2D6 (0.56) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1TSHR | |
| SCHEMBL18926689 | 0.83 | CYP2D6 (0.68) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL22477398 | 0.82 | CYP2D6 (0.35) | CYP2D6SMN1; SMN2CYP3A4TSHRUSP2 | |
| SCHEMBL24508755 | 0.82 | CYP2D6 (0.49) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1TSHR | |
| SCHEMBL18212474 | 0.81 | CYP2D6 (0.52) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1TSHR | |
| SCHEMBL18926690 | 0.81 | CYP2D6 (0.56) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 | |
| SCHEMBL14706855 | 0.81 | CYP2D6 (0.66) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11254696-B2 | Dianilinopyrimidine compound for inhibiting kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2022-02-22 | — | — | US | disclosed |
| US-20210087213-A1 | DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2021-03-25 | — | — | US | disclosed |
| EP-3715343-A1 | DIPHENYLAMINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | Shenzhen TargetRx, Inc. (CN) | 2020-09-30 | — | — | EP | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | CYP2D6 474/4885SMN1; SMN2 3385/4885CYP3A4 649/4885 |
| US-20210087213-A1 | DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | ALK, BRAF, MUSK | CYP2D6 627/4885SMN1; SMN2 641/4885CYP3A4 1557/4885 |
| US-11254696-B2 | Dianilinopyrimidine compound for inhibiting kinase activity | ALK, BRAF, MUSK | CYP2D6 669/4885SMN1; SMN2 693/4885CYP3A4 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.